Effects of a beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advanced cancer.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Effects of a beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advanced cancer.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2355-62. Unique Identifier : AIDSLINE MED/99111192
Triozzi PL; Stevens VC; Aldrich W; Powell J; Todd CW; Newman MJ; The Ohio State University Comprehensive Cancer Center, 410 West; 10th Ave, Columbus, Ohio 43210, USA.

Abstract: The clinical and immunological effects of a vaccine consisting of CTP37, a synthetic peptide corresponding to the COOH-terminal peptide (CTP) of beta-human chorionic gonadotropin (beta-hCG) conjugated to diphtheria toxoid, combined with CRL 1005, a novel synthetic nonionic block copolymer adjuvant, were examined. Twenty-one patients with metastatic, nontrophoblastic cancers received up to four immunizations by i.m. injection of a fixed dose of CTP37 and escalating doses of CRL 1005. Doses of CRL 1005 adjuvant as high as 75 mg were administered with 1 mg of CTP37 without evidence of significant local or systemic toxicity. Immunizations resulted in the production of IgG antibody to beta-hCG. CRL 1005 doses of 3-25 mg appeared to be optimal for antibody induction. Immunizations also resulted in increases in the cellular response of peripheral blood mononuclear cells (PBMCs) to the unconjugated CTP, hCG, and diphtheria toxoid. Responding PBMCs specifically secreted the TH1-associated cytokines IFN-gamma and interleukin (IL)-2 as well as the TH2-associated IL-5 and IL-10. Increased expression of IFN gamma and IL-5 mRNAs by PBMCs 4 h after immunization was also observed. CRL 1005 administered with CTP37 in aqueous solution is well tolerated. The CTP37-CRL 1005 subunit vaccine has the capacity to stimulate potentially beneficial humoral and cellular immune responses in patients with advanced cancer.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE Adjuvants, Immunologic/ADMINISTRATION & DOSAGE/TOXICITY/ *THERAPEUTIC USE Adult Aged Antibody Formation Chorionic Gonadotropin, beta Subunit, Human/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE Diphtheria Toxoid/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Female Human Hypersensitivity, Delayed IgG/BLOOD Immunity, Cellular Interferon Type II/GENETICS Interleukin-2/GENETICS Interleukin-5/GENETICS Male Middle Age Neoplasms/IMMUNOLOGY/*THERAPY Pentosan Sulfuric Polyester/ADMINISTRATION & DOSAGE/ *PHARMACOKINETICS Solutions Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Th1 Cells/IMMUNOLOGY
990530
A9950906

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .